Senate Republicans seek probe of Mylan
EpiPen oversight
Send a link to a friend
[September 21, 2016]
By Brendan Pierson
NEW YORK (Reuters) - Mylan NV <MYL.O> faced
new scrutiny over price hikes for its anti-allergy EpiPen on Tuesday,
with U.S. lawmakers calling for a probe of oversight of the company’s
rebates to government healthcare plans, while West Virginia said it was
investigating whether Mylan defrauded its Medicaid department.
Mylan is grappling with a growing backlash from U.S. consumers,
lawmakers and prosecutors over EpiPen prices, which have risen from
about $100 in 2007 to more than $600 for a pair of the devices. The
EpiPen delivers a dose of epinephrine, an antidote to a severe and
potentially deadly allergic reaction to anything from nuts to bee
stings.
The rising cost has made it difficult for many families to afford
EpiPens, prompting a public outcry that has resonated with legislators.
Mylan Chief Executive Heather Bresch is to testify about the price hikes
on Wednesday before an oversight committee of the House of
Representatives. Bresch is the daughter of Senator Joe Manchin, a
Democrat from West Virginia.
In her prepared testimony, released on Tuesday, Bresch said Mylan was
already moving to address concerns about price by expanding discount
programs and launching a $300 generic version.
She said that, after rebates, fees and costs, the company makes only
about $100 per EpiPen pack, and that a majority of consumers pay less
than $50 out of pocket for a pack.
![](http://archives.lincolndailynews.com/2016/Aug/26/images/ads/current/ldn_sda_062409.png)
Ahead of the hearing, Republicans on the Senate Finance Committee said
they were concerned that Mylan was allowed to inappropriately classify
EpiPen as a generic drug, reducing the potential discounts to the
government’s Medicaid health program for the poor.
“We are concerned that the controls in place, if any, are inadequate to
ensure that Medicaid is receiving the full amount of rebates afforded to
it by law,” the Senate Republicans, led by Orrin Hatch of Utah, said in
a letter to the U.S. Department of Health and Human Services Inspector
General.
Under current law, branded drugs, and generic drugs available from a
single source, are subject to a rebate of at least 23.1 percent of the
average manufacturer price for Medicaid. Non-innovator drugs are subject
to a much lower 13 percent rebate.
The Finance Committee Republicans are asking Inspector General Daniel
Levinson to examine the federal health agency's oversight of the rebate
program.
[to top of second column] |
![](../images/092116pics/news_k19.jpg)
EpiPen auto-injection epinephrine pens manufactured by Mylan NV
pharmaceutical company for use by severe allergy sufferers are seen
in Washington, U.S. August 24, 2016. REUTERS/Jim Bourg/File Photo
![](http://archives.lincolndailynews.com/2016/Sep/21/images/ads/current/brickey_lda_061314.png)
Mylan has said it has complied with all laws and regulations
regarding rebates.
Also on Tuesday, West Virginia Attorney General Patrick Morrisey
said he was investigating the rebates and the possibility that Mylan
violated the state's antitrust law when it sued and settled with a
would-be generic competitor. Mylan spokeswoman Nina Devlin said the
company was cooperating with the investigation.
EpiPen has also posed a cost burden to the federal Medicare health
program for the elderly, according to an analysis from the Kaiser
Family Foundation, a health policy research group. Before rebates,
EpiPen costs for Medicare Part D shot up more than 1,000 percent
between 2007 and 2014, from $7 million to $87.9 million, the report
said.
Devlin, in an emailed statement, said that from 2010 to 2015,
rebates to Medicare Part D plans were up 440 percent, which would
reduce the increase stated by the Kaiser Family report. She said
that any analysis that does not take those specific rebates into
account is fundamentally flawed.
While rebates to Medicare, which are not disclosed by the program,
would have offset the cost to a degree, it was still far higher than
a 164 percent increase in EpiPen prescriptions to Medicare patients,
the Kaiser Family report said.
(Reporting By Brendan Pierson and Caroline Humer in New York;
Editing by Dan Grebler and Alan Crosby)
[© 2016 Thomson Reuters. All rights
reserved.]
Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
![](http://archives.lincolndailynews.com/2016/Sep/21/images/ads/current/humanesociety_sda022411.png) |